References
- Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254–266.
- Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740–3746.
- Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999–2005.
- Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114:2220–2231.
- Alpermann T, Heferlach C, Dicker F, et al. Evaluation of different NPM1 mutations in AML patients according to clinical, cytogenetic and molecular features and impact on outcome. Blood. 2013;122:Abstract 51.
- Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–433.
- Bacher U, Dicker F, Haferlach C, et al. Quantification of rare NPM1 mutation subtypes by digital PCR. Br J Hematol. 2014;167:697–726.
- Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011–4020.
- Pastore F, Greif PA, Schneider S, et al. The NPM1 mutation type has no impact on survival in cytogenetically normal AML. PLoS One 2014;9:e109759.
- Alpermann T, Schnittger S Eder C, et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica. 2016;101:e55–e58.